Loading resource…

The New England Journal of Medicine
Apixaban and rivaroxaban are the most commonly used oral anticoagulants for treating acute venous thromboembolism, yet their comparative bleeding risks remain uncertain. This international trial involved a randomized, open-label design where eligible patients were assigned to receive either apixaban or rivaroxaban for three months. The primary outcome measured was clinically relevant bleeding, and secondary outcomes included mortality rates. The study provides critical insights into the safety profiles of these anticoagulants.
No account needed